References - Neovascular Phenotypes: Retinal Angiomatous Proliferation (RAP) or Type 3 Neovascularization

1. Oeller JN. [Atlas of rare ophthalmoscopic conditions and supplementary plates to the atlas of ophthalmoscopy]: Wiesbaden, Germany; 1904.

2. Slusher MM, Tyler ME. Choroidoretinal vascular anastomoses. Am J Ophthalmol 1980;90:217-22.

3. Boozalis GT, Schachat AP, Green WR. Subretinal neovascularization from the retina in radiation retinopathy. Retina 1987;7:156-61.

4. Kennedy JE, Wise GN. Retinochoroidal vascular anastomosis in uveitis. Am J Ophthalmol 1971;71:1221-5.

5. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769-80.

6. Green WR, Gass JD. Senile disciform degeneration of the macula. Retinal arterialization of the fibrous plaque demonstrated clinically and histopathologically. Arch Ophthalmol 1971;86:487-94.

7. Hartnett ME, Weiter JJ, Garsd A, Jalkh AE. Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol 1992;230:11-9.

8. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2000;107:742-53; discussion 53-4.

9. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416-34.

10. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol 1995;113:1392-8.

11. Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and

chorioretinal anastomosis. Retina 2003;23:741-51.

12. Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG. Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007;245:1131-9.

13. Silva RM, Faria de Abreu JR, Travassos A, Cunha-Vaz JG. Stabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses. Graefes Arch Clin Exp Ophthalmol 2004;242:368-76.

14. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina 2008;28:375-84.

15. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28:201-11.

16. Lafaut BA, Aisenbrey S, Vanden Broecke C, Bartz-Schmidt KU. Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol 2000;84:1269-74.

17. Su D, Lin S, Phasukkijwatana N, et al. An Updated Staging System of Type 3 Neovascularization Using Spectral Domain Optical Coherence Tomography. Retina 2016;36 Suppl 1:S40-S49.

18. Sawa M, Ueno C, Gomi F, Nishida K. Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation. Retina 2014;34:761-7.

19. Marques JP, Lains I, Costa MA, et al. Retinal Angiomatous Proliferation: A Quantitative Analysis of the Fundoscopic Features of the Fellow Eye. Retina 2015;35:1985-91.

20. Kim JH, Lee TG, Kim JW, Kim CG, Cho SW, Han JI. Small retinal haemorrhages accompanied by macular soft drusen: prevalence, and funduscopic and angiographic characteristics. Br J Ophthalmol 2014;98:1066-72.

21. Kim JH, Kim JR, Kang SW, Kim SJ, Ha HS. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol 2013;155:743-9, 9 e1-2.

22. Kim JH, Lee TG, Kim JW, Kim CG, Cho SW, Han JI. Small retinal haemorrhages accompanied by macular soft drusen: prevalence, and funduscopic and angiographic characteristics. Br J Ophthalmol 2014;98:1066-72.

23. Rouvas AA, Papakostas TD, Ntouraki A, Douvali M, Vergados I, Ladas ID. Angiographic and OCT features of retinal angiomatous proliferation. Eye (Lond) 2010;24:1633-42; quiz 43.

24. Kuehlewein L, Dansingani KK, de Carlo TE, et al. Optical Coherence Tomography Angiography of Type 3 Neovascularization Secondary to Age-Related Macular Degeneration. Retina 2015;35:2229-35.

25. Tan AC, Dansingani KK, Yannuzzi LA, Sarraf D, Freund KB. Type 3 Neovascularization Imaged with Cross-Sectional and En Face Optical Coherence Tomography Angiography. Retina 2017;37:234-246.

26. Querques G, Miere A, Souied EH. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. Dev Ophthalmol 2016;56:57-61.

27. Koh AH, Expert PCVP, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013;33:686-716.

28. Liu R, Li J, Li Z, et al. Distinguishing Polypoidal Choroidal Vasculopathy from Typical Neovascular Age-Related Macular Degeneration Based on Spectral Domain Optical Coherence Tomography. Retina 2016;36:778-86.

29. Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 2013;33:1735-62.

30. Brancato R, Introini U, Pierro L, et al. Optical coherence tomography (OCT) angiomatous prolifieration (RAP) in retinal. Eur J Ophthalmol 2002;12:467-72.

31. Politoa A, Napolitano MC, Bandello F, Chiodini RG. The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. Ann Acad Med Singapore 2006;35:420-4.

32. De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2014;158:1228-38 e1.

33. Campa C, Harding SP, Pearce IA, Beare NA, Briggs MC, Heimann H. Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Eye (Lond) 2010;24:1585-9.

34. Gross NE, Aizman A, Brucker A, Klancnik JM, Jr., Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous

proliferation. Retina 2005;25:713-8.

35. Fujimura S, Ueta T, Takahashi H, Obata R, Smith RT, Yanagi Y. Characteristics of fundus autofluorescence and drusen in the fellow eyes of Japanese patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013;251:1-9.

36. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology 1996;103:2042-53.

37. Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G. Retinal angiomatous proliferation: natural history and progression of visual loss. Retina 2009;29:732-9.

38. Silva R, Cachulo ML, Fonseca P, et al. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica 2011;226:110-8.

39. Daniel E, Shaffer J, Ying GS, et al. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 2016;123:609-16.

40. Gharbiya M, Parisi F, Cruciani F, Bozzoni-Pantaleoni F, Pranno F, Abdolrahimzadeh S. Intravitreal Anti-Vascular Endothelial Growth Factor for retinal angiomatous proliferation in treatment-naive eyes: Long-term Functional and Anatomical Results Using A Modified PrONTO-Style Regimen. Retina 2014;34:298-305.

41. Sutter FK, Kurz-Levin MM, Fleischhauer J, Bosch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monbl Augenheilkd 2006;223:376-8.

42. Montero JA, Ruiz-Moreno JM, Sanabria MR, Fernandez-Munoz M. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation. Br J Ophthalmol 2009;93:166-70.

43. McBain VA, Kumari R, Townend J, Lois N. Geographic atrophy in retinal angiomatous proliferation. Retina 2011;31:1043-52.

44. Marques MF, Marques JP, Gil JQ, et al. Long-Term Management of RAP Lesions in Clinical Practice: Treatment Efficacy and Predictors of Functional Improvement. Ophthalmic Res 2016;55:119-25.

45. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal Choroidal Thickness in Retinal Angiomatous Proliferation. Retina 2014;34:1316-22.

46. Hayashi H, Yamashiro K, Gotoh N, et al. CFH and ARMS2 variations in age-related macular degeneration, polypoidal choroidal vasculopathy, and retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 2010;51:5914-9.

47. Caramoy A, Ristau T, Lechanteur YT, et al. Environmental and genetic risk factors for retinal angiomatous proliferation. Acta Ophthalmol 2014;92:745-8.

48. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.

49. Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:89-92.

50. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.

51. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110:392-9.

52. Cantsilieris S, White SJ, Richardson AJ, Guymer RH, Baird PN. Comprehensive analysis of Copy Number Variation of genes at chromosome 1 and 10 loci associated with late age related macular degeneration. PLoS One 2012;7:e35255.

53. Wegscheider BJ, Weger M, Renner W, et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology 2007;114:738-42.

54. Ohkuma Y, Hayashi T, Sakai T, et al. Retinal angiomatous proliferation associated with risk alleles of ARMS2/HTRA1 gene polymorphisms in Japanese patients. Clin Ophthalmol 2014;8:143-8.

55. Tanaka K, Nakayama T, Yuzawa M, et al. Analysis of candidate genes for age-related macular degeneration subtypes in the Japanese population. Mol Vis 2011;17:2751-8.

56. Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathological findings of retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007;245:295-300.

57. Monson DM, Smith JR, Klein ML, Wilson DJ. Clinicopathologic correlation of retinal angiomatous proliferation. Arch Ophthalmol 2008;126:1664-8.

58. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.

59. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-8.

60. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005;123:1644-50.

61. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy. Eur J Ophthalmol 2007;17:979-82.
62. Johnson TM, Glaser BM. Focal laser ablation of retinal angiomatous proliferation. Retina 2006;26:765-72.

63. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. Arch Ophthalmol 2003;121:558-61.

64. Boscia F, Furino C, Prascina F, Delle Noci N, Sborgia L, Sborgia C. Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation. Eur J Ophthalmol 2005;15:513-6.

65. Nakata M, Yuzawa M, Kawamura A, Shimada H. Combining surgical ablation of retinal inflow and outflow vessels with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2006;141:968-70.

66. Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. Retina 2007;27:198-203.

67. Criswell MH, Ciulla TA, Lowseth LA, Small W, Danis RP, Carson DL. Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46:2168-74.

68. Kusserow C, Michels S, Schmidt-Erfurth U. [Chorioretinal anastomosis as unfavourable prognostic factor during photodynamic therapy]. Ophthalmologe 2003;100:197-202.

69. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 2004;138:1077-9.

70. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2006;244:1224-32.

71. Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur J Ophthalmol 2006;16:705-10.

72. van de Moere A, Kak R, Sandhu SS, Talks SJ. Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone. Am J Ophthalmol 2007;143:701-4.

73. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol 2008;246:237-43.

74. Lai TY, Chan WM, Liu DT, Lam DS. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:1877-80.

75. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009;247:1165-71.

76. Montero JA, Fernandez MI, Gomez-Ulla F, Ruiz-Moreno JM. Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III. Eur J Ophthalmol 2009;19:448-51.

77. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina 2008;28:689-95.

78. Matsumoto H, Sato T, Morimoto M, et al. Treat-and-Extend Regimen with Aflibercept for Retinal Angiomatous Proliferation. Retina 2016;36:2282-2289.

79. Scott AW, Bressler SB. Retinal angiomatous proliferation or retinal anastomosis to the lesion. Eye (Lond) 2010;24:491-6.

80. Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina 2009;29:536-44.

81. Saito M, Shiragami C, Shiraga F, Nagayama D, Iida T. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 2008;146:935-41 e1.

82. Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:899-906.

View PDF